A molecular target may lead to drug to fight leukaemia

UQ research may lead to drug to fight leukaemia
Acute myeloid leukaemia cells as appeared in haematology journal Blood

(Medical Xpress)—A molecular 'target' that could lead to a drug to fight leukaemia is in the sights of a team of University of Queensland researchers.

Professor Tom Gonda, from UQ's School of Pharmacy, said the team had found that the 'docking' of one , the Myb protein, with another protein, the p300 protein, was essential for the development of acute myeloid leukaemia, one of the deadliest types of leukaemia.

"Our data identifies the critical role of this Myb-p300 interaction and shows that the disruption of this interaction could lead to a potential therapeutic strategy," he said.

"This finding could lead to our team developing a drug to block this interaction and stop the growth of not only cells but probably the cells of other types of leukaemia as well."

He said the Myb protein was produced by the MYB oncogene, a gene that had the potential to cause cancer and was required for the continued growth of leukaemia cells.

 "However, it's important to note that MYB is also essential for normal so we need an approach for targeting it that won't completely disrupt normal blood cell production.

"Our research shows that normal blood cells can continue to form even when the Myb-p300 interaction is unable to occur, suggesting that a drug that blocks the interaction could be safe for use in patients.

"This work is at a very early stage and, although a high-risk project, it has the potential to produce large benefits in the fight against leukaemia and, possibly, other cancers.

"Drug development and subsequent clinical trials are long processes but we are hopeful that this research has a promising future."

Much of the research was done by Dr Diwakar Pattabiraman while he was a PhD student in Professor Gonda's laboratory.

Professor Gonda said that as Myb was not a conventional target for drugs, the team would also examine other ways to target MYB, such as targeting the genes and proteins that work 'downstream' of MYB.

"If we can block the downstream molecules that are controlled by MYB, we may end up with the same result," he said.

More information: Diwakar R. Pattabiraman, Crystal McGirr, Konstantin Shakhbazov, Valerie Barbier, Keerthana Krishnan, Pamela Mukhopadhyay, Paula Hawthorne, Ann Trezise, Jianmin Ding, Sean M. Grimmond, Peter Papathanasiou, Warren S. Alexander, Andrew C. Perkins, Jean-Pierre Levesque, Ingrid G. Winkler, and Thomas J. Gonda. "Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes." Blood blood-2012-02-413187; published ahead of print March 4, 2014, DOI: 10.1182/blood-2012-02-413187

add to favorites email to friend print save as pdf

Related Stories

Scientists find new drug target for hard-to-treat leukaemia

Mar 30, 2012

(Medical Xpress) -- Cancer Research UK scientists have discovered a promising new approach to treat a type of myeloid leukaemia – a cancer with limited treatment options and relatively poor survival, according to research ...

New cancer gene discovered

Oct 13, 2009

A new cancer gene has been discovered by a research group at the Sahlgrenska Academy at the University of Gothenburg, Sweden. The gene causes an insidious form of glandular cancer usually in the head and neck and in women ...

What makes some cancers more deadly?

Apr 23, 2014

A Flinders University researcher is searching for answers as to why some leukaemia sufferers live a normal lifespan while others succumb to the disease within months.

Recommended for you

Study shows epigenetic changes can drive cancer

Jul 26, 2014

Cancer has long been thought to be primarily a genetic disease, but in recent decades scientists have come to believe that epigenetic changes – which don't change the DNA sequence but how it is 'read' – also play a role ...

User comments